Two potential biomarkers of follicular thyroid adenomas (FTA) were identified in the PC of AuNPs: the aldo-keto reductase family 1 member C1 (AKR1C1) and the heterogeneous nuclear ribonucleoprotein C-like 2 (HNRNPCL2), both proteins linked to cancer progression and malignant transformation [171,172], which could be possible molecular targets and, at the same time, targeted for maximum therapeutic benefit in the treatment of thyroid cancer. The gene discussed is HNRNPCL2; the disease is follicular thyroid adenoma.